Spruce Biosciences, Inc.
SPRB
$60.95
$0.891.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -75.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -75.86% |
| Cost of Revenue | -108.37% | -23.54% | -105.32% | 5.04% | 93.31% |
| Gross Profit | 108.65% | 15.81% | 106.64% | -30.33% | -152.77% |
| SG&A Expenses | 50.75% | -6.89% | -12.20% | -15.35% | 12.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -87.08% | -17.79% | -76.88% | -0.98% | 76.29% |
| Operating Income | 86.71% | 12.53% | 73.18% | -14.72% | -115.64% |
| Income Before Tax | 37.83% | 5.29% | 77.49% | -20.78% | -136.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.83% | 5.29% | 77.49% | -20.78% | -136.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.83% | 5.29% | 77.49% | -20.78% | -136.77% |
| EBIT | 86.71% | 12.53% | 73.18% | -14.72% | -115.64% |
| EBITDA | 86.72% | 12.47% | 73.21% | -14.80% | -115.87% |
| EPS Basic | 73.50% | 7.38% | 79.10% | -12.95% | -132.74% |
| Normalized Basic EPS | 87.79% | 7.38% | 79.10% | -12.95% | -132.74% |
| EPS Diluted | 73.50% | 7.38% | 79.10% | -12.95% | -132.74% |
| Normalized Diluted EPS | 87.79% | 7.38% | 79.10% | -12.95% | -132.74% |
| Average Basic Shares Outstanding | 134.60% | 2.27% | 7.71% | 6.94% | 1.73% |
| Average Diluted Shares Outstanding | 134.60% | 2.27% | 7.71% | 6.94% | 1.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |